Xue Zhang†
Jie Jin- Department of Infectious Diseases, The Affiliated Hangzhou First People’s Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Background: Rotavirus vaccination has been proven to effectively protect against rotavirus gastroenteritis. However, there are concerns about the relationship between rotavirus vaccination and the risk of autoimmune disorders. Thus, we conducted a systematic review and meta-analysis to comprehensively assess the association between rotavirus vaccination and type 1 diabetes (T1D) or celiac disease (CD) risk.
Methods: A systematic review and meta-analysis were conducted to evaluate the type 1 diabetes or celiac disease associated with rotavirus vaccination. The following journal databases were searched to identify potential studies for inclusion: PubMed, Embase, and Cochrane Library databases.
Results: Seven articles involving more than 5,793,055 children were included. Our results showed that rotavirus vaccination does not alter the subsequent risk of T1D (RR 0.94, 95% CI: 0.82–1.09) or CD (RR 0.86, 95% CI: 0.64–1.17) after vaccination. Furthermore, the risk of T1D was not increased or decreased for children fully exposed to rotavirus vaccination (RR 0.86, 95% CI, 0.54–1.36) and for children partially exposed to rotavirus vaccination (RR 1.05, 95% CI, 0.87–1.26). However, younger (<5 years) vaccinated children at the end of study (RR 0.84, 95% CI = 0.75–0.95) may be at a lower risk for T1D than older (≥5 years) vaccinated children (RR 0.93, 95% CI, 0.81–1.07).
Conclusion: The findings of this study suggest that rotavirus vaccination does not appear to be associated with T1D or CD in children. The protective effect of rotavirus vaccination on T1D may be presented by time dependent.
Introduction
Rotavirus infection is the most common cause of acute gastroenteritis in children under 5 years of age worldwide (1). In 2009, the World Health Organization recommended that rotavirus vaccines be included in national immunization programs to prevent rotavirus gastroenteritis (2). Since its inclusion in routine immunization programs, gastroenteritis- and diarrhea-associated mortality has markedly decreased in young children, especially infants (3). Several low-income countries have failed to achieve the recommended population coverage for rotavirus vaccination. One possible reason for this failure is concern regarding a possible relationship between vaccination and autoimmune disorders (4).
Rotavirus infection is a risk factor for type 1 diabetes (T1D) (4) and celiac disease (CD) (5). For T1D, viral protein 7(VP7) protein of rotavirus could bind to human leukocyte antigen molecules associated with T1D and elicit T-cell proliferative responses (6). One Australian study observed a potential association between rotavirus infection and increase in antibodies against insulinoma antigen 2 (7). Animal study also demonstrated that rotavirus infection could accelerate the onset of T1D among genetically susceptible mice that spontaneously develop the disease (8). For CD, researcher found that a subset of anti-transglutaminase IgA antibodies also recognize rotavirus VP7, and such antibodies increase intestinal permeability and induce monocyte activation (9). One epidemiologic study (10) showed that that frequent rotavirus infection predicted a higher risk of CD autoimmunity in children with higher risk of CD. However, the incidence of rotavirus infection has declined since introduction of rotavirus vaccination for children in the worldwide. Therefore, it is biologically plausible that a live, attenuated rotavirus vaccine seemed to reduce the risk of T1D or CD in early childhood. Several studies without a control group have reported that the introduction of rotavirus vaccination was followed by a reduction in the annual increase in the incidence of T1D among children aged 0–4 years (11, 12). Epidemiological studies (13–19) of the association between rotavirus vaccination and the risk for T1D have reported inconsistent findings. In a Finnish study, Hemming-Harlo et al. (14) reported that rotavirus vaccination does not increase the risk of T1D, but may decrease the risk of CD. Conversely, a recent study (19) from the United Kingdom did not find evidence for an effect of rotavirus vaccination on the risk of CD or T1D. Therefore, there is no consensus on the relationships between rotavirus vaccination and the risk of T1D and CD. Due to the aforementioned concerns, we performed a systematic review and meta-analysis to quantitatively data from studies undertaken in different countries regarding the associations between rotavirus vaccination and the risk of T1D and CD.
Methods
Search strategy
This systematic review and meta-analysis are reported in accordance with the Meta-Analysis for Observational Studies in Epidemiology (MOOSE) checklist (20) (Supplementary Table 1) and Preferred Reporting Items of Systematic Reviews and Meta-analysis (PRISMA) guidelines (Supplementary Table 2). PubMed, Embase, and the Cochrane Library were searched to identify relevant peer-reviewed studies published before July 2021. Synonymous terms were combined to develop the search strategy. The search terms used were “rotavirus vaccination OR rotavirus vaccine” and “diabetes OR celiac OR celiac.” In addition, reference lists of the retrieved articles and relevant reviews were reviewed to identify potential studies possibly meeting the inclusion criteria.
Study selection
Observational studies were included if they were published as a peer-reviewed article; had a cross-sectional, case-control, or cohort design; compared the risk of T1D or CD between rotavirus vaccine exposure and non-exposure groups; reported incidence rate ratios (IRRs), odds ratios (ORs), relative risks (RRs), or hazard ratios (HRs); and provided adequate data to allow calculation of risk estimates when adjusted data were not provided. Case reports, case series, animal studies, editorials, and reviews were excluded.
Data extraction and quality assessment
Data were independently extracted by two authors; any discrepancies were resolved through discussion with another author. The extracted data included the first author’s name, publication year, study design, study location, study period, participant characteristics, method of diagnosis of T1D or CD, statistical adjustments, and study quality. In cases where more than one estimate was provided, the most adjusted effect size estimates reported by each study were used. We assessed the methodologic quality of the included observational studies based on the Newcastle-Ottawa Scale (NOS) as recommended by the Cochrane Collaboration (21). The scale assesses studies based on eight criteria, and yields scores ranging from 0 (high risk of bias) to 9 (low risk of bias). Studies with scores > 7 were considered to be of high quality. RCTs were classified as high-quality studies. Summary bias risk assessments were derived for each study.
Data analysis
All analyses were performed in accordance with the Cochrane Collaboration guidelines using Stata 12.0 meta-analysis software (Stata Corp., College Station, TX, United States). Statistical heterogeneity of the included studies was calculated by the χ2 test and I2 statistic; an I2 of >50% or p-value < 0.05 for the Q-statistic was considered to indicate substantial heterogeneity (22). Data were pooled using a random effects model and the generic inverse variance method, as described by DerSimonian and Laird. ORs and 95% confidence intervals (CIs) were calculated for the associations between rotavirus vaccination and subsequent risk of T1D and CD (23). Because of the low absolute risk for T1D or CD in the general population, ORs were considered as approximations of RRs, HRs, and IRRs. Publication bias was evaluated using the Begg funnel plot (24). Publication bias was not formally assessed because each meta-analysis included fewer than 10 studies (25). A p-value < 0.05 was considered to indicate statistical significance.
Results
Search results
After excluding duplicate reports, we identified 166 citations. Based on the titles and abstracts of the papers, 143 were excluded, and the remaining 23 were evaluated on the basis of the full-text articles. Seven studies met the inclusion criteria. Some of the excluded studies, along with reasons for their exclusion, are shown in Figure 1.
Figure 1. Flow chart of the studies considered and finally selected for review.
Descriptive characteristics of the included studies
Table 1 summarizes the included studies in detail. This meta-analysis included five cohort studies, one time-series analysis, and one randomized controlled trial published between 2017 and 2021. All included studies were performed in low-mortality settings, with three in Europe, one in Australia, and the other three in United States. Three studies evaluated the associations between rotavirus vaccines and the risk of T1D and CD, and four assessed the association between rotavirus vaccines and the risk of T1D. Four studies evaluated the RotaTeq vaccine (Merck, West Point, PA, United States) and three evaluated the RotaTeq or Rotarix vaccines (GlaxoSmithKline, Rixensart, Belgium). The age range of children at the end of study was varied among the included studies. All studies had high methodological quality (Supplementary Table 3).
Table 1. Characteristics of the included studies.
Meta-analysis
Seven studies including more than 5,793,055 participants reported the association between rotavirus vaccine and T1D. The results showed that rotavirus vaccination did not increase the risk of subsequent T1D (RR = 0.94; 95% CI = 0.82–1.09; p = 0.41; Figure 2A). Moderate heterogeneity was observed among the studies (I2 = 43.7%). Analysis of the cohort studies alone indicated that the combined RR of T1D was 0.95 (95% CI = 0.81–1.11; p = 0.5; I2 = 50.8%). The RR of T1D was 0.86 (95% CI = 0.54–1.36; p = 0.51; I2 = 87.8%; Figure 3A) after complete rotavirus vaccination, and 1.05 (95% CI = 0.87–1.26; p = 0.62; I2 = 0%; Figure 3B) after partial vaccination. Four studies reported the risk of T1D after RotaTeq exposure (RR = 0.98; 95% CI = 0.82–1.18; p = 0.852; I2 = 0%). In analyses by age at the end of study, vaccinated children aged less than 5 years were at a decreased risk for T1D (RR = 0.84; 95% CI = 0.75–0.95; p = 0.006; I2 = 0%; Figure 4A), whereas those aged over 5 years were not (RR, 0.93; 95% CI, 0.81–1.07; P = 0.299; I2 = 42.1%; Figure 4B).
Figure 2. Rotavirus vaccination exposure and the subsequent risk of (A) T1D and (B) CD.
Figure 3. Rotavirus vaccination exposure and the subsequent risk of T1D (A) complete vaccination (B) partially vaccination.
Figure 4. Rotavirus vaccination exposure and the subsequent risk of T1D (A) aged < 5 years at the end of study and (B) aged ≥ 5 years at the end of study.
Three studies involving 1,008,043 participants evaluated the relationship between rotavirus vaccination and risk of CD (RR = 0.86; 95% CI = 0.64–1.17; p = 0.34; I2 = 62.4%; Figure 2B).
Discussion
To the best of our knowledge, this is the first meta-analysis to evaluate the risk of T1D or CD following rotavirus vaccination. Our results suggested that administration of rotavirus vaccination did not increase the risk of T1D and CD, with pooled RRs of 0.94 (95% CI: 0.82–1.09) and 0.86 (95% CI: 0.64–1.17), respectively. However, a decreased risk of T1D was observed in vaccinated children aged less than 5 years at the end of study.
Rotavirus is the most common viral cause of diarrhea in children (1). A number of studies have evaluated the safety of rotavirus infection in children. Previous epidemiologic studies demonstrated that rotavirus infection may increase the risk of CD or islet cell autoimmunity in children, particularly those with genetic susceptibility to autoimmune disorders (10, 26). Since the introduction of routine rotavirus vaccination worldwide, there has been a significant reduction in the incidence of rotavirus gastroenteritis (27). Therefore, it is reasonable to speculate that exposure to rotavirus vaccine may decrease the risk of T1D and CD. Although a substantial number of clinical trials have assessed the safety of rotavirus vaccines worldwide, evidence for the association between rotavirus vaccination and autoimmune disorders is limited. Two recent reviews (4, 28) have summarized the association between rotavirus vaccination and T1D but addressed the inconsistencies regarding this association. However, these reviews have not provided an overall estimation of the effect of rotavirus vaccination on T1D. In addition, previous systematic review did not evaluate the risk of CD.
T1D and CD have high heritability, estimated to be 70 and 80%, respectively, from twin studies (29, 30). Therefore, studies of the association between rotavirus vaccination and the risk of T1D and CD should take family history of autoimmune disorders into consideration. However, most studies included in this meta-analysis did not adjust for family history of T1D and CD. One included study (18) reported that children with a family history of autoimmune disorders were less likely to receive rotavirus vaccination compared to those without a family history of autoimmune disorders; therefore, it is reasonable to speculate that the strength of the associations in our meta-analysis may have been underestimated. Glanz et al. (18) conducted a sensitivity analysis in children with a family history of T1D, and did not find evidence of an association of rotavirus vaccination with T1D. Environmental exposure during early life plays an important role in the development of autoimmune disorders. Previous studies reported that breastfeeding is associated with a decreased risk of T1D and CD in later life (31). Recent research (18) demonstrated that breastfeeding is positively associated with undervaccination, suggesting that true-negative or -positive associations may be obscured by confounding bias. Unfortunately, the included studies failed to control for breastfeeding; future studies should evaluate the role of early life factors (e.g., breastfeeding) in the risk of T1D and CD among children who have received rotavirus vaccination. Notably, these associations may be modulated by the vaccine dose. If rotavirus vaccination is a protective factor, the risk of T1D and CD in fully vaccinated children should be lower compared to partially vaccinated children. Conversely, if rotavirus vaccination is a risk factor, the risk should be higher in fully compared to partially vaccinated children. Although our subgroup analyses did not identify a significant association, the RR for fully vaccinated children was lower than that for partially vaccinated ones. However, these results should be interpreted with caution due to the limited sample size; further studies are required to clarify this issue.
An unanticipated finding was that vaccination in children aged under 5 years was associated with a decreased risk for T1D, implying that rotavirus vaccination has a time-dependent effect on T1D risk. This may result for two reasons. First, rotavirus vaccine efficacy was proved to wane with time in a recent meta-regression study (32). Therefore, it is reasonable to speculate that at least a portion of children aged over 5 years who received the vaccination during infancy are not protected against rotavirus infection. Second, most cases of rotavirus infection occur in children under 2 years of age, with a peak incidence between 6 and 24 months of age. Thus, the off-target effects are prone to be observed among children aged under 5 years. However, our results relating to the age should be treated with caution due to the limited power of the study.
This systematic review and meta-analysis is the first to provide an overall estimate of the effects of rotavirus vaccination on the subsequent risk of T1D and CD. Our meta-analysis has the advantage of the exclusive inclusion of cohort studies, which are less prone to bias. However, this study had several major limitations. First, there are an unknown number of residual confounders. Further well-designed studies that consider more covariates, such as family history of T1D or CD and breastfeeding, are required to evaluate the association between rotavirus vaccination and the risk of T1D and CD. Second, the duration of follow-up in the included studies was not long enough to determine possible long-term effects. Third, the number of eligible studies and sample size for CD were small, which may have influenced the accuracy of our results. Also, no study reported adjusted estimates by gender, which is an important distinction, as boys and girls are known to have differential risks of CD (33). Future studies are needed before we can have a clear picture of the association between rotavirus vaccination and CD. Fourth, all studies were conducted in Europe or North America; no studies were conducted in Asian or African countries. Therefore, the findings of this meta-analysis cannot be generalized to Asian or African populations. Fifth, only one study (14) intended but failed to explore the risk of other autoimmune diseases due to the rarity of the individual outcomes of interest. Additional studies with larger samples are required to examine the association between rotavirus vaccination and other individual autoimmune disorder.
Conclusion
In conclusion, the results of this meta-analysis failed to demonstrate a role for rotavirus vaccination in the development of CD in children. However, we could not rule out that the protective role of rotavirus vaccination in T1D development was time dependent and further studies are still needed to verify our findings. Our findings support continued worldwide rotavirus vaccination, reducing the burden of rotavirus morbidity in those populations. As there was a small number of studies included in our review, continued evaluation of this association is warranted, and there is a pressing need for new studies with longer follow-up to further explore the relationships between rotavirus vaccination and the risk of T1D and CD in older children.
Data availability statement
The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
XZ and JJ conceived the study and revised the manuscript critically for important intellectual content and made substantial contributions to the design, acquisition, analysis and interpretation of data. X-FX participated in the design, selection, and analysis and interpretation of data. All authors read and approved the final manuscript.
Funding
This study was supported by the Medical Science and Technology Project of Zhejiang Province (Grant No. 2018KY566).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2022.951127/full#supplementary-material
References
1. Bányai K, Estes MK, Martella V, Parashar UD. Viral gastroenteritis. Lancet. (2018) 392:175–86. doi: 10.1016/S0140-6736(18)31128-0
2. Lee PI, Chen PY, Huang YC, Lee CY, Lu CY, Chang MH, et al. Recommendations for rotavirus vaccine. Pediatr Neonatol. (2013) 54:355–9.
3. Burnett E, Parashar UD, Tate JE. Real-world effectiveness of rotavirus vaccines, 2006-19: a literature review and meta-analysis. Lancet Glob Health. (2020) 8:e1195–202. doi: 10.1016/S2214-109X(20)30262-X
4. Burke RM, Tate JE, Jiang B, Parashar UD. Rotavirus and type 1 diabetes-is there a connection? A synthesis of the evidence. J Infect Dis. (2020) 222:1076–83. doi: 10.1093/infdis/jiaa168
5. Størdal K, Kahrs C, Tapia G, Agardh D, Kurppa K, Stene LC. Review article: exposure to microbes and risk of coeliac disease. Aliment Pharmacol Ther. (2021) 53:43–62. doi: 10.1111/apt.16389
6. Honeyman MC, Stone NL, Harrison LC. T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents. Mol Med. (1998) 4:231–9. doi: 10.1007/BF03401920
7. Honeyman MC, Coulson BS, Stone NL, Gellert SA, Goldwater PN, Steele CE, et al. Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes. (2000) 49:1319–24. doi: 10.2337/diabetes.49.8.1319
8. Honeyman MC, Laine D, Zhan Y, Londrigan S, Kirkwood C, Harrison LC. Rotavirus infection induces transient pancreatic involution and hyperglycemia in weanling mice. PLoS One. (2014) 9:e106560. doi: 10.1371/journal.pone.0106560
9. Zanoni G, Navone R, Lunardi C, Tridente G, Bason C, Sivori S, et al. In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med. (2006) 3:e358. doi: 10.1371/journal.pmed.0030358
10. Stene LC, Honeyman MC, Hoffenberg EJ, Haas JE, Sokol RJ, Emery L, et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol. (2006) 101:2333–40. doi: 10.1111/j.1572-0241.2006.00741.x
11. Blumenfeld O, Hampe CS, Shulman LM, Chen R, Laron Z. An attenuation in the incidence of early childhood diabetes correlates with introduction of rotavirus vaccination in Israel. J Infect Dis. (2021) 223:1305–7. doi: 10.1093/infdis/jiaa547
12. Rami-Merhar B, Hofer SE, Fröhlich-Reiterer E, Waldhoer T, Fritsch M. Time trends in incidence of diabetes mellitus in Austrian children and adolescents <15years (1989-2017). Pediatr Diabetes. (2020) 21:720–6. doi: 10.1111/pedi.13038
13. Vaarala O, Jokinen J, Lahdenkari M, Leino T. Rotavirus vaccination and the risk of celiac disease or type 1 diabetes in finnish children at early life. Pediatr Infect Dis J. (2017) 36:674–5. doi: 10.1097/INF.0000000000001600
14. Hemming-Harlo M, Lahdeaho ML, Maki M, Vesikari T. Rotavirus vaccination does not increase type 1 diabetes and may decrease celiac disease in children and adolescents. Pediatr Infect Dis J. (2019) 38:539–41. doi: 10.1097/INF.0000000000002281
15. Perrett KP, Jachno K, Nolan TM, Harrison LC. Association of rotavirus vaccination with the incidence of type 1 diabetes in children. JAMA Pediatr. (2019) 173:280–2. doi: 10.1001/jamapediatrics.2018.4578
16. Rogers MAM, Basu T, Kim C. Lower incidence rate of type 1 diabetes after receipt of the rotavirus vaccine in the United States, 2001-2017. Sci Rep. (2019) 9:7727. doi: 10.1038/s41598-019-44193-4
17. Burke RM, Tate JE, Dahl RM, Saydah S, Imperatore G, Gregg EW, et al. Rotavirus vaccination and type 1 diabetes risk among US children with commercial insurance. JAMA Pediatr. (2020) 174:383–5. doi: 10.1001/jamapediatrics.2019.5513
18. Glanz JM, Clarke CL, Xu S, Daley MF, Shoup JA, Schroeder EB, et al. Association between rotavirus vaccination and type 1 diabetes in children. JAMA Pediatr. (2020) 174:455–62. doi: 10.1001/jamapediatrics.2019.6324
19. Inns T, Fleming KM, Iturriza-Gomara M, Hungerford D. Paediatric rotavirus vaccination, coeliac disease and type 1 diabetes in children: a population-based cohort study. BMC Med. (2021) 19:147. doi: 10.1186/s12916-021-02017-1
20. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. (2000) 283:2008–12. doi: 10.1001/jama.283.15.2008
21. Higgins JP. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. The Cochrane Collaboration. (2014). Available online at: www.cochrane-handbook.org (accessed December 6, 2014)
22. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. (2002) 21:1539–58. doi: 10.1002/sim.1186
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629
25. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ. (2006) 333:597–600. doi: 10.1136/bmj.333.7568.597
26. Kemppainen KM, Lynch KF, Liu E, Lönnrot M, Simell V, Briese T, et al. Factors that increase risk of celiac disease autoimmunity after a gastrointestinal infection in early life. Clin Gastroenterol Hepatol. (2017) 15:694–702.e5. doi: 10.1016/j.cgh.2016.10.033
27. Sun ZW, Fu Y, Lu HL, Yang RX, Goyal H, Jiang Y, et al. Association of rotavirus vaccines with reduction in rotavirus gastroenteritis in children younger than 5 years: a systematic review and meta-analysis of randomized clinical trials and observational studies. JAMA Pediatr. (2021) 175:e210347. doi: 10.1001/jamapediatrics.2021.0347
28. Esposito S, Mariotti Zani E, Torelli L, Scavone S, Petraroli M, Patianna V, et al. Childhood vaccinations and type 1 diabetes. Front Immunol. (2021) 12:667889. doi: 10.3389/fimmu.2021.667889
29. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. (2018) 391:2449–62. doi: 10.1016/S0140-6736(18)31320-5
30. Lebwohl B, Sanders DS, Green PHR. Coeliac disease. Lancet. (2018) 391:70–81. doi: 10.1016/S0140-6736(17)31796-8
31. Szajewska H, Chmielewska A, Pieścik-Lech M, Ivarsson A, Kolacek S, Koletzko S, et al. Systematic review: early infant feeding and the prevention of coeliac disease. Aliment Pharmacol Ther. (2012) 36:607–18. doi: 10.1111/apt.12023
32. Clark A, van Zandvoort K, Flasche S, Sanderson C, Bines J, Tate J, et al. Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials. Lancet Infect Dis. (2019) 19:717–27. doi: 10.1016/S1473-3099(19)30126-4
Keywords: rotavirus vaccine, celiac, diabetes, systematic review, meta
Citation: Zhang X, Xu X-f and Jin J (2022) Rotavirus vaccination and the risk of type 1 diabetes and celiac disease: A systematic review and meta-analysis. Front. Pediatr. 10:951127. doi: 10.3389/fped.2022.951127
Received: 23 May 2022; Accepted: 29 July 2022;
Published: 26 August 2022.
Edited by:
Camille Bréhin, Centre Hospitalier Universitaire de Toulouse, FranceReviewed by:
Praveen Neeli, Baylor College of Medicine, United StatesEric Jeziorski, Centre Hospitalier Universitaire de Montpellier, France
Jinfeng Kang, Temple University, United States
Copyright © 2022 Zhang, Xu and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jie Jin, jinjie20222022@126.com
†These authors have contributed equally to this work